Initial Seed Financing Secured August 21, 2007 • admin • Funding, Pharmaceuticals Following the incorporation of the company, Countervail was able to secure its initial seed funding from an Austrian pharmaceutical company that synthetically manufactures galantamine which is the company’s initial drug under development. Related News Countervail Corporation presents significant results of orally dosed AverTox (galantamine) for improved survival from exposure to lethal levels of soman at the CounterACT Symposium held at the New York Academy of Sciences. June 17, 2015 Countervail Corporation presents significant results of i.m. dosed AverTox (galantamine) for improved survival from exposure to lethal levels of soman at the CounterACT Symposium held in Denver Colorado. June 7, 2014
